FrancophonIA/ELRC3.0 huggingface dataset:
English: In addition to the ADRs described in tables 4 and 5, the following ADRs with an incidence of less than 0.1% were associated with the use of capecitabine monotherapy based on a pooled analysis from clinical safety data from 7 clinical trials including 949 patients (2 phase III and 5 phase II clinical trials in metastatic colorectal cancer and metastatic breast cancer): cardiomyopathy, cardiac failure, sudden death, and ventricular extrasystoles.
Croatian: Uz nuspojave opisane u tablicama 4 i 5, sljedeće nuspojave s incidencijom manjom od 0,1% su bile povezane s uporabom kapecitabina kao monoterapije, temeljeno na analizi združenih podataka o kliničkoj sigurnosti primjene iz 7 kliničkih ispitivanja na 949 bolesnika (2 faze III i 5 faza II kliničkih ispitivanja u bolesnika s metastatskim kolorektalnim karcinomom i metastatskim karcinomom dojke): kardiomiopatija, zatajenje srca, iznenadna smrt i ventrikularne ekstrasistole.
English: A person whose body weight is 80 kg and height is 1.80 m has a body surface area of 2.00 m2 and should take 5 tablets of 500 mg two times daily.
Croatian: Osoba čija tjelesna težina iznosi 80 kg, a visina 1,80 m ima tjelesnu površinu od 2,00 m mora uzimati 5 tableta od 500 mg dvaput dnevno.
English: Patients should be carefully monitored for ophthalmological complications such as keratitis and corneal disorders, especially if they have a prior history of eye disorders.
Croatian: Bolesnike treba pomno nadzirati zbog moguće pojave oftalmoloških komplikacija, poput keratitisa i poremećaja rožnice, osobito ako imaju poremećaje oka u anamnezi.
English: The overall safety profile of capecitabine is based on data from over 3000 patients treated with capecitabine as monotherapy or capecitabine in combination with different chemotherapy regimens in multiple indications.
Croatian: Ukupni sigurnosni profil kapecitabina se temelji na podacima od preko 3000 bolesnika koji su liječeni kapecitabinom kao monoterapijom ili kapecitabinom kao dijelom različitih kemoterapijskih protokola, u različitim indikacijama.
English: At the beginning of a treatment cycle, if a treatment delay is indicated for either capecitabine or the other medicinal product(s), then administration of all therapy should be delayed until the requirements for restarting all medicinal products are met.
Croatian: Ako je na početku liječenja indicirana odgoda liječenja bilo kapecitabinom, bilo drugim lijekom (lijekovima), primjena svih lijekova mora se odgoditi dok ne budu zadovoljeni uvjeti za početak liječenja svim lijekovima.
English: Number of 150 mg tablets and/or 500 mg tablets per administration (each administration to be given morning and evening)
Croatian: Broj tableta od 150 mg i/ili 500 mg po jednoj primjeni (svaka doza uzima se ujutro i navečer)
English: A combination study with capecitabine and folinic acid indicated that folinic acid has no major effect on the pharmacokinetics of capecitabine and its metabolites.
Croatian: Ispitivanje kombinirane primjene kapecitabina i folinatne kiseline pokazalo je da folinatna kiselina nema većeg utjecaja na farmakokinetiku kapecitabina i njegovih metabolita.
English: • During pregnancy and lactation,
Croatian: • Trudnoća i dojenje,
English: Some of the ADRs are reactions commonly seen with the combination medicinal product (e.g. peripheral sensory neuropathy with docetaxel or oxaliplatin, hypertension seen with bevacizumab); however an exacerbation by capecitabine therapy can not be excluded.
Croatian: Neke od nuspojava su reakcije koje se često viđaju pri primjeni kombinacijskog lijeka (npr. periferna senzorna neuropatija kod docetaksela ili oksaliplatina, povišeni krvni tlak kod bevacizumaba); ipak pogoršanje istih zbog uzimanja kapecitabina se ne može isključiti.
English: In addition to the ADRs described in tables 4 and 5, and based on the above pooled analysis from clinical safety data from 7 clinical trials, encephalopathy was also associated with the use of capecitabine monotherapy with an incidence of less than 0.1%.
Croatian: Uz nuspojave opisane u tablicama 4 i 5 te temeljeno na gore navedenoj analizi združenih podataka o kliničkoj sigurnosti primjene iz 7 kliničkih ispitivanja, encefalopatija je također bila povezana s uzimanjem kapecitabina kao monoterapije, s incidencijom manjom od 0,1%.
English: Cardiovascular toxicity (e.g. PR- and QT-interval prolongation) was detectable in cynomolgus monkeys after intravenous administration (100 mg/kg) but not after repeated oral dosing (1379 mg/m2/day).
Croatian: Kardiovaskularna toksičnost (npr. produljenje PR i QT intervala) utvrđena je u cinomolgus majmuna nakon intravenske primjene (100 mg/kg), ali ne i nakon ponovljene oralne doze (1379 mg/m na dan).
English: PHARMACEUTICAL FORM AND CONTENTS 60 film-coated tablets
Croatian: OBLIK I SADRŽAJ 60 filmom obloženih tableta
English: Tell your doctor immediately if you experience any of these symptoms.
Croatian: Teva odmah i obratite se liječniku ako se pojave neki od ovih simptoma:
English: There was no clinically significant effect of bevacizumab on the pharmacokinetic parameters of capecitabine or its metabolites in the presence of oxaliplatin.
Croatian: Nisu uočeni klinički značajni učinci bevacizumaba na farmakokinetičke parametre kapecitabina ili njegovih metabolita u prisutnosti oksaliplatina.
English: Also, you need to be particularly careful if you are taking any of the following: - gout medicines (allopurinol), - blood-thinning medicines (coumarin, warfarin), - medicines for seizures or tremors (phenytoin), - certain medicines used to treat various cancers or virus infection (interferon alpha), - radiotherapy and certain medicines used to treat cancer (folinic acid, oxaliplatin, bevacizumab,
Croatian: Također, trebate biti posebno oprezni ako uzimate neki od ovih lijekova: - lijekove za giht (alopurinol), - lijekove protiv zgrušavanja krvi (kumarin, varfarin), - lijekove protiv epilepsije ili tremora (fenitoin), - određene lijekove za liječenje različitih rakova ili virusne infekcije (interferon alfa), - zračenje i određeni lijekovi za liječenje raka (folna kiselina, oksaliplatin, bevacizumab,
English: • cold sores or other herpes infections
Croatian: • herpes simplex ili druge infekcije herpesa
English: Table 4 lists ADRs associated with the use of capecitabine monotherapy based on a pooled analysis of safety data from three major studies including over 1900 patients (studies M66001, SO14695, and SO14796).
Croatian: U Tablici 4 nalazi se popis nuspojava povezanih s primjenom kapecitabina u monoterapiji koji se temelji na združenoj analizi sigurnosnih podataka iz tri glavna ispitivanja na više od 1900 bolesnika (M66001, SO14695, SO14796).
English: What Capecitabine Teva looks like and contents of the pack
Croatian: Teva izgleda i sadržaj pakiranja
English: Other medicines and Capecitabine Teva
Croatian: Drugi lijekovi i Kapecitabin
English: Median overall survival time was 703 days (95% CI: 671; 745) in patients treated with capecitabine-containing regimens and 683 days (95% CI: 646; 715) in patients treated with 5-FU-containing regimens.
Croatian: Medijan ukupnog vremena preživljenja iznosio je 703 dana (95% CI: 671; 745) u bolesnika liječenih terapijskim protokolima koji su sadržavali kapecitabin i 683 dana (95% CI: 646; 715) u bolesnika liječenih terapijskim protokolima koji su sadržavali 5-FU.
English: Capecitabine is first metabolised by hepatic carboxylesterase to 5'-DFCR, which is then converted to 5'-DFUR by cytidine deaminase, principally located in the liver and tumour tissues.
Croatian: Kapecitabin se najprije metabolizira jetrenom karboksilesterazom u 5'-DFCR, koji se pomoću citidin deaminaze pretvara u 5'-DFUR koji se uglavnom nalazi u jetri i tumorskim tkivima.
English: Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administered precursor of the cytotoxic moiety 5-fluorouracil (5-FU).
Croatian: Kapecitabin je necitotoksični fluoropirimidin karbamat, koji djeluje kao oralno primijenjeni prethodnik citotoksične čestice 5-fluorouracila (5-FU).
English: (neuropathy) - if you have calcium imbalances (seen in blood tests) - if you have diabetes - if you cannot keep food or water in your body because of severe nausea and vomiting - if you have diarrhoea - if you are, or become dehydrated - if you have imbalances of ions in your blood (electrolyte imbalances, seen in tests) - if you have a history of eye problems as you may need extra monitoring of your eyes - if you have a severe skin reaction
Croatian: (neuropatiju)) - ako imate poremećaj razine kalcija (otkriva se krvnim pretragama) - ako imate šećernu bolest - ako ne možete zadržati hranu ili vodu u vašem tijelu usljed jake mučnine ili povraćanja - ako imate proljev - ako ste dehidrirani ili ste dehidrirali - ako imate poremećaj ravnoteže iona u krvi (poremećaj ravnoteže elektrolita, što se otkriva krvnim pretragama) - ako ste ranije imali očnih tegoba jer će vam možda biti potrebna dodatna kontrola očiju - ako imate tešku kožnu reakciju.
English: Capecitabine Teva should be permanently discontinued in patients who experience a severe skin reaction during treatment.
Croatian: Teva potrebno je trajno obustaviti u bolesnika koji razviju tešku kožnu reakciju tijekom liječenja.
English: Table 9 Key efficacy results for the non-inferiority analysis of Study NO16967 PRIMARY ANALYSIS
Croatian: Tablica 9 Ključni rezultati djelotvornosti iz analize neinferiornosti u ispitivanju NO 16967
English: Gender, presence or absence of liver metastasis at baseline, Karnofsky Performance Status, total bilirubin, serum albumin, ASAT and ALAT had no statistically significant effect on the pharmacokinetics of 5'-DFUR, 5-FU and FBAL.
Croatian: Spol, postojanje ili nepostojanje jetrenih metastaza na početku liječenja, opći status po Karnofskom, ukupni bilirubin, serumski albumin, AST i ALT nisu imali statistički značajan učinak na farmakokinetiku 5'-DFUR, 5
English: There is some evidence that dexpanthenol is effective for hand-foot syndrome prophylaxis in patients treated with Capecitabine.
Croatian: Postoje dokazi o tome da je dekspantenol djelotvoran za profilaksu sindroma šaka-stopalo u bolesnika liječenih lijekom
English: You must not take Capecitabine Teva if you are pregnant or think you might be.
Croatian: Teva ako ste trudni ili mislite da biste mogli biti trudni.
English: • inflammation of the veins (thrombophlebitis)
Croatian: • upala vena (tromboflebitis)
English: Finally, β-ureido-propionase cleaves FUPA to α-fluoro-β-alanine
Croatian: Na kraju, β-ureido-propionaza cijepa FUPA do α-fluoro-βalanina (FBAL) koji se izlučuje urinom.
English: • pain in the joints, or in the limbs (extremities), chest or back
Croatian: • bol u zglobovima ili udovima (ekstremitetima), prsnom košu ili leđima
English: Some of these side effects are more common when capecitabine is used with other medicines for the treatment of cancer.
Croatian: Neke od tih nuspojava javljaju se češće ako se kapectiabin primjenjuje zajedno s drugim lijekovima za liječenje raka.
English: You must inform your doctor if you know that you have an allergy or over-reaction to this medicine, - if you previously have had severe reactions to fluoropyrimidine therapy (a group of anticancer medicines such as fluorouracil), - if you are pregnant or breast-feeding, - if you have severely low levels of white cells or platelets in the blood (leucopenia, neutropenia or thrombocytopenia), - if you have severe liver or kidney problems, - if you know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase (DPD), - if you are being treated now or have been treated in the last 4 weeks with brivudine as part of herpes zoster (chickenpox or shingles) therapy.
Croatian: Morate obavijestiti svog liječnika ako znate da ste alergični ili preosjetljivi na ovaj lijek, - ako ste već imali jake reakcije na terapiju fluoropirimidinom (na lijekove za liječenje malignih bolesti poput fluorouracila), - ako ste trudni ili ako dojite, - ako imate izrazito snižene razine bijelih krvnih stanica ili trombocita (leukopenija, neutropenija ili trombocitopenija), - ako imate teške bolesti jetre ili bubrega, - ako znate da nemate nikakvu aktivnost enzima dihidropirimidin dehidrogenaze (DPD), - ako primate terapiju ili ste primali terapiju s brivudinom kao dio liječenja herpes zostera (vodene kozice ili herpes zoster) unutar zadnja 4 tjedna.
English: Hand and foot syndrome also known as hand-foot skin reaction or palmar-plantar erythrodysesthesia or chemotherapy induced acral erythema.
Croatian: Sindrom šaka-stopalo poznat i kao kožna reakcija na šakama i stopalima ili palmarno-plantarna eritrodizestezija ili akralni eritem izazvan kemoterapijom.
English: There is no data on capecitabine and impact on fertility.
Croatian: Nema podataka o utjecaju kapecitabina na plodnost.
English: Tablet coating Macrogol (400) Hypromellose Titanium dioxide (E171) Yellow iron oxide (E172) Red iron oxide (E172)
Croatian: Ovojnica tablete makrogol (400) hipromeloza titanijev dioksid (E171) željezov oksid, žuti (E172) željezov oksid, crveni (E172).
English: Discontinue permanently or If physician deems it to be in the patient's best interest to continue, interrupt until resolved to grade 0-1
Croatian: • Stupanj 4 -1. pojavljivanje Trajno obustaviti ili ako liječnik smatra da je nastavak liječenja u interesu bolesnika, prekinuti dok se ne svede na stupanj
English: In repeat-dose toxicity studies, daily oral administration of capecitabine to cynomolgus monkeys and mice produced toxic effects on the gastrointestinal, lymphoid and haemopoietic systems, typical for fluoropyrimidines.
Croatian: U ispitivanju toksičnosti ponovljene doze, oralna dnevna primjena kapecitabina izazvala je u cinomolgus majmuna i miševa toksične učinke na gastointestinalnom, limfnom i hematopoteskom sustavu, što je tipično za fluoropirimidine.
English: Elderly patients (see section 4.2)
Croatian: Stariji bolesnici (vidjeti dio 4.2)
English: If no toxicity is observed in patients ≥60 years of age treated with a reduced capecitabine starting dose in combination with docetaxel, the dose of capecitabine may be cautiously escalated to 1250 mg/m2 twice daily.
Croatian: Ako se u tih bolesnika ne uoče znakovi toksičnosti pri primjeni smanjene početne doze kapecitabina u kombinaciji s docetakselom, doza kapecitabina može se oprezno povećavati do 1250 mg/m dvaput dnevno.
English: If you have an unrecognised DPD deficiency and take capecitabine, you are at an increased risk of acute early-onset of severe forms of the side effects listed under section 4 Possible side effects.
Croatian: Ako ne znate da imate nedostatak DPD-a, a uzimate kapecitabin, imate povećan rizik od akutnog ranog nastupa teških oblika nuspojava navedenih u dijelu 4. Moguće nuspojave.
English: • In patients with severe leukopenia, neutropenia, or thrombocytopenia,
Croatian: • Bolesnici s teškom leukopenijom, neutropenijom ili trombocitopenijom,
English: The pooled analysis includes 3097 patients treated with capecitabine-containing regimens and 3074 patients treated with 5-FU-containing regimens.
Croatian: Analiza združenih podataka obuhvatila je 3097 bolesnika liječenih terapijskim protokolima koji su sadržavali kapecitabin i 3074 bolesnika liječenih terapijskim protokolima koji su sadržavali 5FU.
English: • In patients with severe renal impairment (creatinine clearance below 30 ml/min),
Croatian: • Bolesnici s teškim oštećenjem bubrežne funkcije (klirens kreatinina manji od 30 ml/min),
English: - Tablet coating: macrogol 400, hypromellose, titanium dioxide (E171), yellow iron oxide (E172),
Croatian: - Ovojnica tablete: makrogol 400, hipromeloza, titanijev dioksid (E171), žuti željezov oksid (E172), crveni željezov oksid (E172).
English: If you forget to take Capecitabine Teva
Croatian: Ako ste zaboravili uzeti Kapecitabin Teva
English: Within each frequency grouping, ADRs are presented in order of decreasing seriousness.
Croatian: Unutar svake od tih kategorija nuspojave su navedene od najozbiljnijih prema manje ozbiljnima.
English: • pain or altered/abnormal sensation in the mouth, pain in the jaw
Croatian: • bol u ustima ili promijenjen/poremećen osjećaj u ustima, bol u čeljusti
English: An analysis of safety data in patients ≥60 years of age treated with capecitabine monotherapy and an analysis of patients treated with capecitabine plus docetaxel combination therapy showed an increase in the incidence of treatment-related grade 3 and 4 adverse reactions and treatment-related serious adverse reactions compared to patients <60 years of age.
Croatian: Analiza podataka o sigurnosti primjene kod bolesnika starih 60 i više godina liječenih monoterapijom kapecitabina i analiza bolesnika liječenih kombinacijom kapecitabina i docetaksela, pokazala je povećanje incidencije nuspojava 3. i 4. stupnja povezanih s terapijom i ozbiljnih nuspojava povezanih s terapijom, u usporedbi s bolesnicima mlađim od 60 godina.
English: A population pharmacokinetic analysis was carried out after capecitabine treatment of 505 patients with colorectal cancer dosed at 1250 mg/m2 twice daily.
Croatian: Populacijska farmakokinetska analiza provedena je u skupini od 505 bolesnika s kolorektalnim karcinomom nakon liječenja kapecitabinom u dozi od 1250 mg/m2 dvaput dnevno.
English: Cytochrome P-450 2C9 substrates
Croatian: Supstrati izoenzima 2C9 citokroma P450
English: The pharmacokinetics of capecitabine have been evaluated over a dose range of 502-3514 mg/m2/day.
Croatian: 5.2 Farmakokinetička svojstva Farmakokinetika kapecitabina procjenjivana je u rasponu dnevne doze od 502 do 3514 mg/m2.
English: • decreases in the number of white blood cells or red blood cells (seen in tests),
Croatian: • smanjeni broj bijelih ili crvenih krvnih stanica (otkriva se krvnim pretragama)
English: The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min) is increased compared to the overall population (see sections 4.2 and 4.3).
Croatian: Incidencija nuspojava 3. ili 4. stupnja u bolesnika s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina 30-50 ml/min) povećana je u usporedbi s ukupnom populacijom (vidjeti dijelove 4.2 i 4.3).
English: Phase I studies evaluating the effect of capecitabine on the pharmacokinetics of either docetaxel or paclitaxel and vice versa showed no effect by capecitabine on the pharmacokinetics of docetaxel or paclitaxel (Cmax and AUC) and no effect by docetaxel or paclitaxel on the pharmacokinetics of 5'-DFUR.
Croatian: Ispitivanja faze I u kojima se ocjenjivao učinak kapecitabina na farmakokinetiku docetaksela ili paklitaksela i obratno nisu pokazala nikakav učinak kapecitabina na farmakokinetiku docetaksela ili paklitaksela (Cmax i AUC) niti je utvrđen učinak docetaksela ili paklitaksela na farmakokinetiku 5'
English: • problems with liver function (seen in blood tests) and increased blood bilirubin (excreted by the liver)
Croatian: • problemi s funkcijom jetre (kao što pokazuju krvne pretrage) i povišene razine bilirubina u krvi
English: Table 7 Key efficacy results for the non-inferiority analysis of Study NO16966 PRIMARY ANALYSIS
Croatian: Tablica 7 Ključni rezultati djelotvornosti iz analize o neinferiornosti u ispitivanju NO 16966
English: Not applicable *According to the National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) Common Toxicity Criteria (version 1) or the Common Terminology Criteria for Adverse Events (CTCAE) of the Cancer Therapy Evaluation Program, US National Cancer Institute, version 4.0.
Croatian: Nije primjenjivo *prema općim kriterijima toksičnosti skupine za klinička ispitivanja Kanadskoga nacionalnog instituta za rak (National Cancer Institute of Canada Clinical Trial Group - NCIC CTG), verzija 1 ili uobičajenom nazivlju kriterija za štetne događaje prema programu evaluacije terapije karcinoma
English: • Stomatitis: if you have pain, redness, swelling or sores in your mouth and/or throat.
Croatian: • Stomatitis: osjećate li bol, crvenilo, oteklinu ili imate rane u ustima i/ili grlu.
English: Capecitabine Teva contains capecitabine, which itself is not a cytostatic medicine.
Croatian: Kapecitabin Teva sadrži kapecitabin, koji sam po sebi nije citostatik.
English: Hand-foot syndrome
Croatian: Sindrom šaka-stopalo
English: The median time to progression was 186 days (capecitabine + docetaxel) vs. 128 days (docetaxel alone).
Croatian: Medijan vremena do progresije bolesti iznosio je 186 dana (kombinacija kapecitabina i docetaksela) odnosno 128 dana (samo docetaksel).
English: In all studies combined, the following covariates were statistically significantly associated with an increased risk of developing HFS: increasing capecitabine starting dose (gram), decreasing cumulative capecitabine dose (0.1*kg), increasing relative dose intensity in the first six weeks, increasing duration of study treatment (weeks), increasing age (by 10 year increments), female gender, and good ECOG performance status at baseline (0 versus ≥1).
Croatian: U svim ispitivanjima sljedeći nezavisni čimbenici su bili statistički značajno povezani s povećanim rizikom razvoja sindroma šakastopalo: povećana početna doza kapecitabina (u gramima), smanjena kumulativna doza kapecitabina (0,1*kg), povećanje intenziteta relativne doze u prvih šest tjedana, produženje liječenja u ispitivanju (tjedni), starija životna dob (u intervalima od 10 godina), ženski spol i dobar ECOG status na početku liječenja (0 nasuprot ≥ 1).
English: Hypo- or hypercalcaemia
Croatian: Hipokalcijemija ili hiperkalcijemija
English: Day 1, prior to XELOX, every 3 weeks
Croatian: 30 - 90 min prvoga dana, prije XELOX protokola, svaka 3 tjedna
English: No information is available on hepatic impairment due to cirrhosis or hepatitis.
Croatian: Nisu dostupne informacije za bolesnike s oštećenjem jetrene funkcije uzrokovanom cirozom ili hepatitisom.
English: The elimination half-life (t1/2 in hours) of capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 0.85, 1.11, 0.66, 0.76 and 3.23 respectively.
Croatian: Poluvrijeme uklanjanja (t1/2 u satima) kapecitabina, 5'-DFCR, 5'-DFUR, 5-FU i FBAL iznosilo je 0,85; 1,11; 0,66;0,76 i 3,23.
English: DPD deficiency cannot be precisely defined, it is known that patients with certain homozygous or certain compound heterozygous mutations in the DPYD gene locus (e.g. DPYD*2A, c.1679T>G, c.2846A>T and c.1236G>A/HapB3 variants), which can cause complete or near complete absence of DPD enzymatic activity (as determined from laboratory assays), have the highest risk of lifethreatening or fatal toxicity and should not be treated with Capecitabine Teva (see section 4.3).
Croatian: Iako deficit DPD-a nije precizno definiran, poznato je da bolesnici s određenim homozigotnim ili određenim višestrukim heterozigotnim mutacijama u lokusu gena DPYD (npr. varijantama DPYD*2A, c.1679T>G, c.2846A>T i c.1236G>A/HapB3), koje mogu uzrokovati potpun ili gotovo potpun izostanak enzimske aktivnosti DPD-a (određuje se laboratorijskim testovima), imaju najveći rizik od po život opasne ili smrtonosne toksičnosti te se ne smiju liječiti lijekom Kapecitabin Teva (vidjeti dio 4.3).
English: In case you are using coumarin anticoagulants (containing e.g. phenprocoumon), stopping capecitabine might require that your doctor adjusts your anticoagulant dose.
Croatian: Ako slučajno uzimate antikoagulanse kumarinskog tipa (koji sadrže npr. fenprokumon), nakon prestanka uzimanja kapecitabina možda će Vam liječnik morati prilagoditi dozu antikoagulansa.
English: • irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack (infarction)
Croatian: • nepravilni otkucaji i lupanje srca (aritmije), bol u prsištu i srčani udar (infarkt)
English: Currently, no comparative data are available on capecitabine monotherapy in colorectal cancer in comparison with first line combination regimens.
Croatian: Za sada nema usporednih podataka između monoterapije kapecitabinom i kombinacijskih protokola u prvoj liniji liječenja kolorektalnoga karcinoma.
English: There is no relevant use of capecitabine in the paediatric population in the indications colon, colorectal, gastric and breast cancer.
Croatian: Nema relevantne primjene kapecitabina u pedijatrijskoj populaciji za indikaciju karcinoma kolona, kolorektalnog karcinoma, karcinoma želuca i karcinoma dojke.